Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
-
Samba TV Launches Project Gravity, an Independent Data Activation Platform for the Agentic Era
-
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
-
Prairie Provident Reports on AGM Voting Results
-
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
-
Mountain America Credit Union Ranked Among USA Today’s Top 10 Workplaces for Third Consecutive Year
-
Modaxo Enters into Agreement to Acquire the Public Transit Business from Conduent
-
nVent to Participate in Upcoming Investor Conference
-
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at
-
Peace Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
-
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
-
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
-
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
-
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
-
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
-
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
-
Equus Announces First Quarter Net Asset Value
-
Whale Dynamic Joins Hitch Open World AI Championships as Official Mapping Technology Partner, Delivering Centimeter-Accurate HD Map of Tianmen Mountain for 2026 Racing Season
-
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical O
-
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
-
North American Construction Group Ltd. Announces Voting Results of Annual and Special Meeting of Shareholders
-
Imperial Announces Voting Results for the Election of Directors
-
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
-
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
-
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
-
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
-
AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit
-
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
-
TruGolf Reports First Quarter 2026 Results
-
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccR
-
Canadian Net REIT Announces 2026 First-Quarter Results and a Distribution Increase
-
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline
-
Zodiac Partners II, LLC Provides an Update to its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash
-
NVIDIA Announces Upcoming Events for Financial Community
-
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
-
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
-
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
-
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
-
Navient declares second quarter common stock dividend
-
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2
-
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
-
Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting
-
Legend Biotech Announces Presentations at ASCO 2026
-
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
-
Banco Comercial Português, S.A., announces the commencement of duties of the Board of Directors for the 2026-2029 four-year term
-
Banqup delivers 40,3% y/y growth in subscription revenue in Q1 2026
-
The Math Underlying the Success of Tort Reforms – Florida Property Insurance and Beyond
-
AMSC to Report Fourth Quarter and Fiscal Year 2025 Financial Results on May 27, 2026
-
CVB Financial Corp. Names George A. Borba Jr. Chairman of the Board; Prior Chairman Hal W. Oswalt Transitions to Vice Chairman
-
Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group

